Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS) [2]

International Journal of Laboratory Hematology

Volumn 29, Issue 5, 2007, Pages 395-397

  Sanders, J ^a   Crawford, B ^a   Gibson, J ^a   Joy Ho, P ^a   Iland, H ^a   Joshua, D ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN; DEOXYPYRIDINOLINE;

ADULT; AGED; BONE DENSITY; BONE RADIOGRAPHY; BONE TURNOVER; CANCER SCREENING; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOREARM; HIP; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SPINE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPOROSIS; PARAPROTEINEMIAS;

EID: 34548472189     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00860.x     Document Type: Letter

References (9)

1. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., Koutsoukou V., Gika D., Anagnostopoulos X., Padadimitriou C., Terpos E. Dimopoulos A. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. Journal of Clinical Oncology 23, 8580 8587.
2. Berenson J.R., Lichtenstein A., Porter L., Dimopoulos M.A., orodoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M., Blacklock H., Bell R., Simeonoe J.F., Reitsma D.J., Heffernan M., Seaman J. Knight R.D. (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Journal of Clinical Oncology 16, 593 602.
3. Corso A., Arcaine L., Magiacavelli S., Astori C., Orlandi E., Lorenzi A., Passamonti F., Klersy C., Pascutto C., Canevari-Sciorati A. Lazzarino M. (2001) Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 86, 394 398.
4. Diamond T., Levy S., Smith A., Day P. Manoharan A. (2001) Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Internal Medicine Journal 31, 272 278.
5. Hernandez J.M., Suquia B., Queizan J.A., Fisac R.M., Sanchez J.J., Fernandez-Calvo F.J., Garcia-Sanz R., Oliver C., Barez A., Calmuntia M.J., Garcia-Frade J., Portero J.A., Lopez R., Aguilera C., Navajo J.A. San-Miguel J.F. (2004) Bone remodelation markers are useful in the management of monoclonal gammopathies. Haematology Journal 5, 480 488.
6. Joshua D.E. (2001) Editorial: bone disease in multiple myeloma: new markers, new treatments. Internal Medicine Journal 31, 261 263.
7. Martin A., Garcia-Sanz R., Hernandez J., Blade J., Suquia B., Fernandez-Calvo J., Gonzalez M., Mateo G., Orfao A. San-Miguel J.F. (2002) Pamidronate induces bone formation in patients with smoldering or indolent myeloma, with no significant anti-tumour effect. British Journal of Haematology 118, 239 242.
8. McCloskey E.V., MacLennan I.C., Drayson M.T., Chapman C., Dunn J. Kanis J.A. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Medical Journal 30, 172 173.
9. Ruggiero S.I., Mehrotra B. Rosenberg T.J. (2004) Engroff. Osteonecrosis of the jaws associated with the use of bisphoponates: a review of 63 cases. Journal of Oral Maxillofac Surgery 62, 527 534.